Compressible-Coated Pharmaceutical Compositions and Tablets and Methods of Manufacture

• US 20110129530A1
• Filed: 11/30/2010
• Published: 06/02/2011
• Est. Priority Date: 11/30/2009
• Status: Abandoned Application

• Current Assignee: Adare Pharmaceuticals, Inc.
• Original Assignee: Eurand Incorporated (Abbvie Incorporated)
• Inventors: Lai, Jin-Wang, Kramer, Craig, Clevenger, James M., Venkatesh, Gopi M.
• Application Number:
  US12/956,543
• Publication Number:
  US 20110129530A1
• Time in Patent Office: Days
• US Class Current: 424/470
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/221 with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/2081 with microcapsules or coated microparticles according to A61K9/50
• CPC Class Codes: A61K 9/5015 Organic compounds, e.g. fats, sugars
• CPC Class Codes: A61K 9/5073 having two or more different coatings optionally including drug-containing subcoatings
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/04 : Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system

Abstract

There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, or a mixture thereof, and other optional, pharmaceutically acceptable excipients wherein the orally disintegrating tablet (ODT) or rapidly dispersing tablet (RDT) composition having acceptable tableting, organoleptic, and pharmacokinetic properties.

Claims

1. A pharmaceutical composition comprising compressible-coated microparticles comprising:

a. drug particles comprising a drug and/or a pharmaceutically acceptable salt, ester, polymorph, or solvate thereof;

b. at least one modified-release membrane layer comprising a water-insoluble polymeric material disposed over the drug particles; and

c. a compressible coating layer comprising a non-polymeric sweetener.

2. The pharmaceutical composition of claim 1, wherein said modified-release membrane layer is applied for a weight gain of from about 5% to about 50% by weight based on the total weight of the compressible-coated microparticles.

3. The pharmaceutical composition of claim 1, wherein said modified-release membrane is a taste-masking layer, wherein said taste-masking layer is applied for a weight gain of from about 5% to about 50% by weight based on the total weight of the compressible-coated microparticles.

4. The pharmaceutical composition of claim 3, wherein said taste-masking layer further comprises a gastrosoluble pore-former, wherein the ratio of water-insoluble polymeric material to gastrosoluble pore-former in said layer varies from about 95:

5 to 50;

50 and the total layer is applied for a weight gain of from about 5% to about 50% by weight based on the total weight of the compressible-coated microparticles and wherein said taste-masking layer effectively masks the taste of the drug and/or pharmaceutically acceptable salt, ester, or solvate thereof and provides substantially complete release of the dose upon entry into the stomach.

5. The pharmaceutical composition of claim 3, further comprising a sealant layer comprising a hydrophilic polymer disposed over said drug particles, wherein said sealant layer is applied for a weight gain of from about 1% to about 10% by weight based on the total weight of the compressible-coated microparticles.

6. The pharmaceutical composition of claim 3, further comprising a second membrane layer comprising a water-insoluble polymer in combination with a gastrosoluble pore-forming polymer disposed over said taste-masking layer, wherein said second membrane layer is applied for a weight gain of from about 5% to about 50% by weight based on the total weight of the compressible-coated microparticles, and wherein said first and/or second coating(s) substantially masks the taste of the drug particles.

7. The pharmaceutical composition of claim 3, wherein said pharmaceutical composition releases at least about 70% of said drug or a pharmaceutically acceptable salt, ester, solvate, or combination thereof, upon entering the stomach or within 30 minutes when tested for dissolution in simulated gastric fluid or 0.01 N HCl in United States Pharmacopoeia Apparatus 2 (paddles at 50 rpm in 900 mL of pH 1.2 or pH 2.0 buffer).

8. The pharmaceutical composition of claim 1, further comprising a sealant layer comprising a hydrophilic polymer disposed over said drug particles.

9. The pharmaceutical composition of claim 1, wherein said drug particles comprise crystalline drug material, a drug granule, a drug-containing pellet by controlled spheronization, or a drug-layered bead.

10. The pharmaceutical composition of claim 1, wherein said modified-release coated membrane layer is applied for a weight gain of from about 5% to about 25% by weight based on the total weight of the compressible-coated microparticles.

11. The pharmaceutical composition of claim 10, wherein said pharmaceutical composition provides a sustained-release profile of said drug or a pharmaceutically acceptable salt, ester, solvate, or combination thereof, upon entry into the gastrointestinal tract or when tested for dissolution in United States Pharmacopoeia Apparatus 2 (paddles at 50 rpm at 37°

C. in 700 mL of pH 1.2 buffer for first 2 hrs, followed by further testing at pH 6.8 obtained by the addition of 200 mL of a pH modifier).

12. The pharmaceutical composition of claim 10, wherein said membrane layer further comprises an enteric polymer wherein the ratio of water-insoluble polymeric material to enteric polymer in said first membrane varies from about 9:

1 to 1;

2 and the total membrane is applied for a weight gain of from about 10% to about 40% by weight based on the total weight of the compressible-coated microparticles.

13. The pharmaceutical composition of claim 10, further comprising a second membrane, wherein the second membrane comprises a water-insoluble polymer in combination with an enteric polymer, wherein the ratio of water-insoluble polymer to enteric polymer in said second membrane varies from about 9:

1 to 1;

2 and the total membrane is applied for a weight gain of from about 10% to about 40% by weight based on the total weight of the compressible-coated microparticles.

14. The pharmaceutical composition of claim 5, wherein said hydrophilic polymeric material is selected from the group consisting of hypromellose, hydroxypropylcellulose, polyvinyl pyrrolidone (povidone), and mixtures thereof.

15. The pharmaceutical composition of claim 1, wherein said modified-release coated drug microparticles have an average particle size of about 500 μ

m or less.

16. The pharmaceutical composition of claim 3, wherein said taste-masking layer comprises one or more polymers selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylic acid-methylmethacrylate copolymers, neutral copolymers based on ethyl acrylate and methylmethacrylate, and mixtures thereof.

17. The pharmaceutical composition of claim 4, wherein said gastrosoluble pore-former is a polymer selected from the group consisting of maltrin, aminoalkyl methacrylate copolymer available under the trade name of Eudragit®

(type E100 or EPO), poly(vinylacetate-diethylaminoacetate) available under the trade name of AEA®

from Sankyo Company Limited, Tokyo (Japan), and combinations thereof.

18. The pharmaceutical composition of claim 4, wherein said gastrosoluble pore-former is an organic or inorganic pore-former selected from the group consisting of calcium carbonate, calcium phosphate, calcium saccharide, calcium succinate, calcium tartrate, ferric acetate, ferric hydroxide, ferric phosphate, magnesium carbonate, magnesium citrate, magnesium hydroxide, magnesium phosphate, and mixtures thereof.

19. The pharmaceutical composition of claim 10, wherein said modified-release membrane material comprises a water-insoluble polymer is selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylic acid-methylmethacrylate copolymers, neutral copolymers based on ethyl acrylate and methylmethacrylate, and mixtures thereof.

20. The pharmaceutical composition of claim 12, wherein said enteric polymer is selected from the group consisting of hypromellose phthalate, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, pH-sensitive methacrylic acid/methylmethacrylate copolymers (e.g., Eudragit®

L, S and FS polymers), shellac, and mixtures thereof.

21. An orally disintegrating tablet (ODT) or a rapidly dispersing tablet (RDT) composition comprising a taste-masked and/or modified-release coated drug-containing cores of claim 1 or 10 comprising:

a. drug particles comprising a therapeutically effective amount of a drug and/or a pharmaceutically acceptable salt, ester, or solvate thereof;

b. one or more polymeric membranes, each membrane comprising a water-insoluble polymer or optionally a water-insoluble and gastrosoluble polymeric blend material;

c. a compressible-coating with a non-polymeric sweetener selected from the group consisting of sucralose, lactitol, sorbitol, maltitol, or a mixture thereof, disposed over modified release coated drug particles of step (b.); and

d. rapidly dispersing granules comprising (i) a disintegrant and (ii) a sugar alcohol, a saccharide, or a mixture thereof, at a ratio of from about 90;

10 to about 99;

1.

22. The orally disintegrating tablet (ODT) composition of claim 21 comprising microparticles of a drug and/or a pharmaceutically acceptable salt, solvate, coated with one or more taste-masking membranes, exhibit one or more of the following properties:

i. acceptable hardness and friability suitable for packaging in bottles and blister packaging, storage, transportation, commercial distribution, and end use;

ii. disintegration on contact with saliva in the oral cavity in about 60 seconds forming a smooth, easy-to-swallow suspension with a pleasant taste (no grittiness or aftertaste), meeting the specification of not more than 30 seconds in the <

USP 701>

Disintegration Test;

iii. taste-masked drug particles exhibit smooth mouthfeel (non-gritty) and no aftertaste;

iv. provide rapid, substantially-complete release of the dose upon entry into the stomach, as evident by meeting the dissolution specifications of about 85% of the dose in about 45 minutes in 900 mL of 0.01N HCl buffer when tested for dissolution using USP Apparatus 2 (paddles @ 75 rpm);

v. enhances the probability of achieving bioequivalence to reference listed drug, non-ODT product of equal strength, patient convenience and compliance with the dosing regimen.

24. The method for treating a disease state comprising administering a modified release composition to a patient in need thereof, in accordance with claim 1 wherein manufacturing modified-release coated drug particles comprises the steps of:

a. applying a first coating layer comprising a water-insoluble polymeric material for a weight gain of from 5% w/w to about 20% w/w, onto microparticles containing a drug and/or a pharmaceutically acceptable salt, solvate, polymorph, or ester thereof, with desired particle size specifications;

b. applying an optional second coating layer comprising a water insoluble-enteric polymer blend material at a ratio of water insoluble polymer to enteric polymer of from 9;

1 to 1;

2 for a weight gain of from 10% w/w to about 40% w/w, onto drug particles;

c. applying a compressible coating with a non-polymeric material disposed over the modified-release coated drug particles of step (b);

d. producing rapidly dispersing granules with an average particle size of not more than 400 μ

m, comprising a sugar alcohol, a saccharide, or a mixture thereof, and a super disintegrant with an average particle size of not more than 30 μ

m, by granulating said mixture at a ratio of from 99/1 to 90/10 using water as a granulating fluid and drying in a fluid bed dryer or in a tray drying;

e. blending compressible coated modified-release drug particles from (c), rapidly dispersing microgranules from (d) and additional excipients comprising one or more flavoring agents, one or more colorants, a sweetener, additional disintegrant, and a diluent such as microcrystalline cellulose; and

f. compressing the blend from (e) into orally disintegrating tablets using a rotary tablet press equipped with an external lubrication system,

wherein (1) one or more said modified-release coating layers effectively mask the taste of said drug and/or the pharmaceutically acceptable salt, ester, or solvate thereof,

(2) said orally disintegrating tablet rapidly disintegrates in the oral cavity of a patient into a smooth, easy-to-swallow suspension containing modified-release coated drug particles exhibiting non-gritty mouthfeel and no aftertaste.

25. The method for treating a disease state comprising administering a modified release composition to a patient in need thereof, in accordance with claim 1 wherein manufacturing said composition comprises the steps of:

a. applying a taste masking membrane comprising a water-insoluble polymer in combination with a reverse enteric polymer at a ratio of water insoluble polymer to reverse enteric polymer of from 9;

1 to 1;

1 for a weight gain of from 10% w/w to about 40% w/w, onto microparticles containing a drug and/or a pharmaceutically acceptable salt, solvate, polymorph, or ester thereof;

b. applying a controlled-release layer comprising a water-insoluble polymer in combination with an enteric polymer at a ratio of water insoluble polymer to enteric polymer of from 9;

1 to 1;

2 for a weight gain of from 10% w/w to about 20% w/w, onto microparticles containing a drug and/or a pharmaceutically acceptable salt, solvate, polymorph, or ester thereof, with desired particle size specifications;

c. applying a compressible coating layer comprising a non-polymeric sweetener selected from the group consisting of sucralose, lactitol, sorbitol, maltitol, or a mixture thereof, onto taste-masked drug microparticles of step (a.) or controlled-release coated drug microparticles of step (b.)

d. preblending pharmaceutically acceptable excipients comprising one or more flavoring agents, one or more colorants, a sweetener, glidant colloidal silicon dioxide, disintegrant, and diluent microcrystalline cellulose, and further blending with compressible coated taste-masked drug microparticles from (a.) and compressible coated controlled-release coated drug microparticles from (b.) and rapidly dispersing microgranules or compressible diluents; and

e. compressing the blend from (d.) into orally disintegrating tablets or rapidly dispersing tablets using a rotary tablet press.

27. The method for treating or preventing a disease state comprising administering a modified-release composition to a patient in need thereof, wherein said orally disintegrating tablets comprising modified-release coated microparticles in accordance with claim 25, exhibit one or more of the following properties:

i. acceptable hardness and friability suitable for packaging in bottles and blister packaging, storage, transportation, commercial distribution, and end use;

ii. disintegration on contact with saliva in the oral cavity in about 60 seconds forming a smooth, easy-to-swallow suspension with a pleasant taste (no grittiness or aftertaste), meeting the specification of not more than 30 seconds in the <

USP 701>

Disintegration Test;

iii. modified-release coated drug particles exhibit smooth mouthfeel (non-gritty) and no aftertaste;

iv. provide rapid, substantially-complete or desired target release profile of the drug upon entry into the stomach, as evident by meeting the drug release specifications when dissolution tested in USP Apparatus 2 (paddles @ 50 rpm at 37°

C. in 900 mL of 0.1N HCl or in 700 mL of 0.1N HCl for first 2 hrs, followed by further testing in 900 mL of pH 6.8 buffer); and

v. enhances the probability of achieving bioequivalence to reference listed drug, non-ODT product of equal strength, or reduction in frequency of dosing by providing appropriate physicokinetic profiles, patient convenience and compliance with the dosing regimen.

23. A method for treating or preventing a gastrointestinal disorder comprising administering to a patient in need thereof a taste-masked composition comprises the steps of:

a. applying one or more polymeric membranes onto drug particles containing a drug and/or a pharmaceutically acceptable salt, solvate, polymorph, or ester thereof, with a desired particle size distribution; and

b. a compressible coating with a non-polymeric material disposed over the modified-release coated drug particles of step (a);

c. producing rapidly dispersing granules with an average particle size of not more than 400 μ

m, comprising a sugar alcohol, a saccharide, or a mixture thereof, and a super disintegrant with an average particle size of not more than 30 μ

m, by granulating said mixture at a ratio of from 99/1 to 90/10 using water as a granulating fluid and drying in a fluid bed dryer or in a tray drying;

d. blending compressible coated taste-masked drug particles from (b), rapidly dispersing microgranules from (c) and additional excipients comprising one or more flavoring agents, one or more colorants, a sweetener, additional disintegrant, and a diluent such as microcrystalline cellulose; and

e. compressing the blend from (d) into orally disintegrating tablets using a rotary tablet press equipped with an external lubrication system,

wherein (1) one or more said taste-masking layers effectively mask the taste of said drug and/or the pharmaceutically acceptable salt, ester, or solvate thereof,

(2) said orally disintegrating tablet rapidly disintegrates in the oral cavity of a patient into a smooth, easy-to-swallow suspension containing taste-masked particles exhibiting non-gritty mouthfeel and no aftertaste.

26. The method for treating or preventing a disease state comprising administering a modified-release composition to a patient in need thereof, in accordance with claim 23 or 24 wherein manufacturing microparticles comprising taste-masking or modified-release coatings disposed over drug particles further comprises the steps of applying a compressible coating layer comprising a non-polymeric sweetener selected from the group consisting of sucralose, lactitol, sorbitol, maltitol, or a mixture thereof, onto taste-masked or modified-release coated drug particles.